학술논문

The Association between Medical Comorbidity and Healthcare Effectiveness Data and Information Set (Hedis) Measures of Treatment Initiation and Engagement for Alcohol and Other Drug Use Disorders
Document Type
article
Source
Substance Abuse. 40(3)
Subject
Health Services and Systems
Health Sciences
Brain Disorders
Substance Misuse
Health Services
Prevention
Clinical Research
Digestive Diseases
4.1 Discovery and preclinical testing of markers and technologies
Detection
screening and diagnosis
Cardiovascular
Good Health and Well Being
Adolescent
Adult
Ambulatory Care
Cardiovascular Diseases
Cohort Studies
Comorbidity
Digestive System Diseases
Emergency Service
Hospital
Endocrine System Diseases
Female
Health Services Research
Hospitalization
Humans
Logistic Models
Male
Mental Disorders
Mental Health Services
Metabolic Diseases
Middle Aged
Musculoskeletal Diseases
Nervous System Diseases
Patient Participation
Respiratory Tract Diseases
Retrospective Studies
Substance-Related Disorders
United States
Wounds and Injuries
Young Adult
Alcohol-induced disorders
comorbidity
complications and therapy
health care
health services research
quality indicators
substance-related disorders
Public Health and Health Services
Psychology
Substance Abuse
Health services and systems
Public health
Clinical and health psychology
Language
Abstract
Background: Medical comorbidity may influence treatment initiation and engagement for alcohol and other drug (AOD) use disorders. We examined the association between medical comorbidity and Healthcare Effectiveness Data and Information Set (HEDIS) treatment initiation and engagement measures.Methods: We used electronic health record and insurance claims data from 7 US health care systems to identify patients with AOD use disorders between October 1, 2014, and August 15, 2015 (N = 86,565). Among patients identified with AOD use disorders in outpatient and emergency department (ED) settings, we examined how Charlson/Deyo comorbidity index scores and medical complications of AOD use were associated with treatment initiation. Among those who initiated treatment in inpatient and outpatient/ED settings, we also examined how comorbidity and AOD use-related medical complications were associated with treatment engagement. Analyses were conducted using generalized estimating equation logistic regression modeling.Results: Among patients identified as having an AOD diagnosis in outpatient and ED settings (n = 69,965), Charlson/Deyo comorbidity index scores of 2 or more were independently associated with reduced likelihood of initiation (risk ratio [RR] = 0.80, 95% confidence interval [CI] = 0.74, 0.86; reference score = 0), whereas prior-year diagnoses of cirrhosis (RR = 1.25, 95% CI = 1.12, 1.35) and pancreatic disease (RR = 1.34, 95% CI = 1.15, 1.56) were associated with greater likelihood of initiation. Among those who were identified in outpatient/ED settings and initiated, higher comorbidity scores were associated with lower likelihood of engagement (score 1: RR = 0.85, 95% CI = 0.76, 0.94; score 2+: RR = 0.61, 95% CI = 0.53, 0.71).Conclusion: Medical comorbidity was associated with lower likelihood of initiating or engaging in AOD treatment, but cirrhosis and pancreatic disease were associated with greater likelihood of initiation. Interventions to improve AOD treatment initiation and engagement for patients with comorbidities are needed, such as integrating medical and AOD treatment.